Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
98 participants
OBSERVATIONAL
2017-05-30
2019-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Performance of Glomerular Filtration Rate Measurement Using CT Urography in Patients With a GFR Below 60 mL/Min/1.73 m²
NCT07042698
Consistency Between Measures of Renal Function in ICU Patients
NCT05385094
Healthy Transitions in Late Stage Kidney Disease
NCT02085837
Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach
NCT03979534
Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.
NCT04070885
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Despite decades of research, the mechanisms involved in the development and progression of CKD remain unclear, and there is a lack of preventative therapies. Women are relatively protected against CKD, but this topic has been little studied.
The kidney is very sensitive to hypoxia and its chronic oxygen depravation is the final step in the pathogenesis of CKD. A special MRI application, called BOLD-MRI, has the ability to measure renal tissue oxygenation in humans. In a recent BOLD-MRI study, the investigators demonstrated that cortical oxygenation is significantly higher in women than in men, which may explain women's lower susceptibility to declining renal function. However, whether this is true under different dietary conditions (high salt-low salt), and whether renal oxygenation changes throughout the menstrual cycle is unknown and will be assessed in this study.
Renal oxygenation depends on its perfusion. Renal micro-perfusion can be measured with contrast-enhanced ultrasound (CEUS) and is expressed as PI (perfusion index). CEUS is a recent imaging technique that combines conventional ultrasound with the administration of a microbubble contrast agent (a lipid or albumin-enveloped gas compound). The microbubbles are inert and eliminated by pulmonary and hepatic systems within one hour of administration. They are not nephrotoxic and have no major side effects. Whether there are differences in renal perfusion as measured with CEUS between men and women with and without CKD will be also assessed in this study.
Oxygenation of the kidneys does not only depend on their perfusion, but also on their consumption, mainly related to tubular active sodium transport. Thus, their oxygenation is lower in the case of a high salt diet compared to a low salt diet. This has been proven in men, but not in women.
Recently, another MRI technique called 23Na MRI was used to measure the amount of salt stored in the skin and muscles. It is possible that the cutaneous and muscular capacity of storing salt according to dietary salt intake is lower in men, but this has not, at present, been examined.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. Healthy and pre-menopausal women without CKD
A total of 45 healthy and pre-menopausal women (\<50 years old) will be recruited. Thirty of them are not on oral anticonception; 15 will be examined at each visit during their follicular phase, 15 during their luteal phase. Fifteen are on oral contraception.
Three visits will take place:
* V1: after 5 days of a high salt diet (adding 6g of salt/day on top of regular diet), patients will undergo renal ultrasound (Doppler and CEUS), renal functional MRI (BOLD and phase contrast) and Na23 muscle and skin MRI.
* V2: after 5 days of low salt diet (dietary instructions), the same exams mentioned above will be repeated
* V3: renal CEUS will be performed before and after an oral protein load (1g/kg) or after SL nitroglycerin (0.2mg).
The day before each visit, a 24h urine collection will be performed in order to measure renal salt excretion.
high-salt diet (V1) and low salt diet (V2)
Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
Contrast-enhanced ultrasound (CEUS)
Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
functional MRI
Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
Pilocarpine test
Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
2. Pre-menopausal women with CKD
A total of 30 women with CKD will be recruited and undergo the same visits as outlined above
high-salt diet (V1) and low salt diet (V2)
Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
Contrast-enhanced ultrasound (CEUS)
Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
functional MRI
Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
3. Post-menopausal women without CKD
Fifteen post-menopausal women will undergo the same exams as outlined above
high-salt diet (V1) and low salt diet (V2)
Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
Contrast-enhanced ultrasound (CEUS)
Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
functional MRI
Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
4. Healthy men
A total of thirty age-and sex-matched men (15 below and 15 above 50 years old) will undergo the same exams as above.
high-salt diet (V1) and low salt diet (V2)
Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
Contrast-enhanced ultrasound (CEUS)
Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
functional MRI
Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
Pilocarpine test
Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
5.Men with CKD
Fifteen men with CKD will undergo the same exams as outlined above
Contrast-enhanced ultrasound (CEUS)
Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
functional MRI
Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
high-salt diet (V1) and low salt diet (V2)
Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
Contrast-enhanced ultrasound (CEUS)
Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
functional MRI
Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
Pilocarpine test
Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No drugs (psychoactive substances used for non-medical purposes) /medicine.
* Blood pressure \<135/85mmHg.
* Renal function (eGFR \>90ml/min/1.73m2) and absence of albuminuria.
* Regular menstrual cycle.
* No pregnancy.
* Understanding and signature of the informed consent.
* Age ≥ 18 years old and \<50 years old.
* Possibility to stop the treatment during the day of the study.
* Reduced renal function (eGFR 15-60 ml/min/1.73m2) or eGFR 60-90 ml/min/1.73m2 with the presence of albuminuria \>300 mg/j.
* Understanding and signature of the informed consent.
* Age ≥ 50 years old.
* Absence of menstruation.
* No drugs consumption.
* No medicine, or possibility to stop it two days before the study.
* Blood pressure \<135/85mmHg.
* Renal function (eGFR \>90ml/min/1.73m2) and absence of albuminuria.
* Understanding and signature of the informed consent.
* Age ≥ 18 years old, but matched with the age of pre- aor post-menopausal women
* No drugs consumption.
* No medicine, or possibility to stop it two days before the study.
* Blood pressure \<135/85mmHg.
* Renal function (eGFR \>90ml/min/1.73m2) and absence of albuminuria.
* Understanding and signature of the informed consent.
Exclusion Criteria
* Known allergy to one of the study compounds (furosemide, Sonovue).
* Autosomal dominant polycystic kidney disease.
* Ingestion of corticosteroids or other immunosuppressants.
* Volume overload or heart failure.
* eGFR \< 15ml/min/1.73m2 or dialysis.
* Hypersensitivity to nitrous derivatives or to one of the excipients present in the composition.
* History of heart disease (ischemic heart disease, valve and/or rhythmic).
* Low blood pressure (systolic blood pressure \<100mmHg)
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
Centre Hospitalier Universitaire Vaudois
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gregoire Wuerzner; MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Menno Pruijm, PD MD
Role: PRINCIPAL_INVESTIGATOR
CHUV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHUV, nephrology service
Lausanne, Canton of Vaud, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-01971
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.